Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania: Lessons from a cross-sectional surveillance study
暂无分享,去创建一个
M. Mizinduko | S. Khamadi | K. Ganesan | E. Bahemana | P. Agaba | Peter G L Coakley | A. Peter | Caroline Mavere | Neha Shah | Elizabeth H Lee | Anange Lwilla | Seth Bwigane | Adela Peter | Joy Makando | Benjamin Peter | Boniphase Julu
[1] J. Livezey,et al. Prevalence and Correlates of Viral Load Suppression and HIV Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] E. Maina,et al. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya , 2021, Medicine.
[3] C. Tseng,et al. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. , 2021, The Lancet. Global health.
[4] N. Rakhmanina,et al. HIV Drug Resistance in Children and Adolescents: Always a Challenge? , 2021, Current Epidemiology Reports.
[5] I. Scott,et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review , 2021, BMJ Open.
[6] B. Mmbaga,et al. “At home, no one knows”: A qualitative study of retention challenges among women living with HIV in Tanzania , 2020, PloS one.
[7] S. Bhatt,et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study , 2020, The Lancet Global Health.
[8] Benjamin R Phelps,et al. Multimonth dispensing of antiretroviral therapy for HIV. , 2020, The lancet. HIV.
[9] V. Colizzi,et al. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon , 2020, AIDS Research and Therapy.
[10] P. Kaleebu,et al. Population-based monitoring of HIV drug resistance early warning indicators in Uganda: A nationally representative survey following revised WHO recommendations , 2020, PloS one.
[11] N. Kiwanuka,et al. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda , 2020, PloS one.
[12] Y. Assefa,et al. HIV drug resistance early warning indicators in Ethiopia: Variability at regional and health facility levels and trend over time. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[13] P. Wekesa,et al. Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya , 2019, BMC Public Health.
[14] F. Kiweewa,et al. “The number of clients is increasing but the supplies are reducing”: provider strategies for responding to chronic antiretroviral (ARV) medicines stock-outs in resource-limited settings: a qualitative study from Uganda , 2019, BMC Health Services Research.
[15] D. Cooper,et al. HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme , 2019, BMC Public Health.
[16] G. Rutherford,et al. Supportive interventions to improve retention on ART in people with HIV in low- and middle-income countries: A systematic review , 2018, PloS one.
[17] M. Egger,et al. HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling , 2018, Journal of virus eradication.
[18] J. Matheka,et al. Challenges to and opportunities for the adoption and routine use of early warning indicators to monitor pediatric HIV drug resistance in Kenya , 2018, BMC Pediatrics.
[19] S. Iacob,et al. Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical Considerations , 2017, Front. Pharmacol..
[20] R. Murphy,et al. Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program , 2017, AIDS Research and Therapy.
[21] P. Mee,et al. Identifying gaps in HIV policy and practice along the HIV care continuum: evidence from a national policy review and health facility surveys in urban and rural Kenya , 2017, Health policy and planning.
[22] N. Dean,et al. Assessment of the World Health Organization’s HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia , 2016, PloS one.
[23] S. Oka,et al. Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD , 2016, Tropical medicine & international health : TM & IH.
[24] S. Billong,et al. Monitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization Recommendations , 2015, PloS one.
[25] A. Thorson,et al. Antiretroviral treatment coverage in a rural district in Tanzania – a modeling study using empirical data , 2015, BMC Public Health.
[26] M. Tanner,et al. An assessment of the supply chain management for HIV/AIDS care and treatment in Kilombero and Ulanga districts in southern Tanzania , 2015 .
[27] B. Kilama,et al. Monitoring prevention or emergence of HIV drug resistance: results of a population-based foundational survey of early warning indicators in mainland Tanzania , 2014, BMC Infectious Diseases.
[28] D. Pillay,et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.
[29] D. Bennett,et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.